Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2025)
Top general drug manufacturer stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Overview Zen Rating Price Value Growth Financials Momentum Sentiment Forecast

General Drug Manufacturers is Zen Rated A and is the 3rd ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Price	Price Target	Upside/Downside	Consensus	Analysts	Fore. Revenue Growth	Fore. Earnings Growth	Forecast ROE	Forecast ROA
GRFS	GRIFOLS SA	$6.85B	$9.97	$10.30	3.31%	Hold	1	8.48%	128.12%	17.25%	4.74%
LLY	ELI LILLY & CO	$693.36B	$732.58	$935.33	27.68%	Strong Buy	9	16.98%	36.20%	240.26%	43.50%
NVS	NOVARTIS AG	$244.99B	$126.55	N/A	N/A	N/A	N/A	1.16%	13.57%	45.00%	18.10%
GSK	GSK PLC	$80.59B	$39.67	N/A	N/A	N/A	N/A	2.09%	29.44%	107.53%	26.84%
ABBV	ABBVIE INC	$371.68B	$210.40	$222.60	5.80%	Buy	10	6.80%	96.77%	-16,601.59%	22.15%
AMRN	AMARIN CORP PLC	$311.07M	$15.04	$12.00	-20.21%	Strong Sell	1	-6.84%	N/A	-19.57%	-13.58%
BIIB	BIOGEN INC	$19.39B	$132.22	$173.92	31.54%	Buy	13	-2.29%	14.63%	13.73%	8.55%
BMY	BRISTOL MYERS SQUIBB CO	$96.03B	$47.18	$53.88	14.19%	Hold	8	-3.78%	32.31%	64.34%	11.85%
AZN	ASTRAZENECA PLC	$247.69B	$79.90	N/A	N/A	N/A	N/A	5.14%	29.33%	20.35%	8.09%
SNY	SANOFI	$125.00B	$49.48	$65.00	31.37%	Hold	1	4.55%	5.94%	8.52%	4.77%
GILD	GILEAD SCIENCES INC	$140.17B	$112.97	$124.00	9.76%	Strong Buy	12	3.07%	22.01%	64.73%	22.85%
JNJ	JOHNSON & JOHNSON	$426.69B	$177.17	$175.80	-0.77%	Buy	10	3.97%	8.80%	40.54%	16.45%
MRK	MERCK & CO INC	$210.11B	$84.12	$94.40	12.22%	Hold	5	4.32%	17.12%	56.92%	23.73%
SCLX	SCILEX HOLDING CO	$123.53M	$17.76	$630.00	3,447.30%	Strong Buy	1	34.46%	N/A	N/A	-183.13%
PFE	PFIZER INC	$140.77B	$24.76	$26.83	8.37%	Hold	6	-1.35%	17.40%	17.12%	7.37%
AMGN	AMGEN INC	$154.89B	$287.71	$307.50	6.88%	Hold	10	2.18%	21.87%	165.42%	13.98%
OGN	ORGANON & CO	$2.45B	$9.42	$14.00	48.62%	Buy	2	0.26%	19.75%	151.44%	8.22%
NSRX	NASUS PHARMA LTD	N/A	$8.10	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MIRA	MIRA PHARMACEUTICALS INC	$26.12M	$1.37	N/A	N/A	N/A	N/A	N/A	N/A	-1,371.99%	-900.41%

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Aug 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the #1 top general drug manufacturer stock out of 19 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Grifols Sa (NASDAQ:GRFS) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: B, Financials: C, and AI: B.

Grifols Sa (NASDAQ:GRFS) has a Due Diligence Score of 33, which is -9 points lower than the general drug manufacturer industry average of 42. Although this number is below the industry average, our proven quant model rates GRFS as a "A".

GRFS passed 13 out of 38 due diligence checks and has average fundamentals. Grifols Sa has seen its stock return 9.56% over the past year, overperforming other general drug manufacturer stocks by 23 percentage points.

Grifols Sa has an average 1 year price target of $10.30, an upside of 3.31% from Grifols Sa's current stock price of $9.97.

Grifols Sa stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Grifols Sa, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Eli Lilly & Co (NYSE:LLY)

Eli Lilly & Co (NYSE:LLY) is the #2 top general drug manufacturer stock out of 19 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Eli Lilly & Co (NYSE:LLY) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: B.

Eli Lilly & Co (NYSE:LLY) has a Due Diligence Score of 65, which is 23 points higher than the general drug manufacturer industry average of 42.

LLY passed 26 out of 38 due diligence checks and has strong fundamentals. Eli Lilly & Co has seen its stock lose -22.08% over the past year, underperforming other general drug manufacturer stocks by -8 percentage points.

Eli Lilly & Co has an average 1 year price target of $935.33, an upside of 27.68% from Eli Lilly & Co's current stock price of $732.58.

Eli Lilly & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Eli Lilly & Co, 88.89% have issued a Strong Buy rating, 0% have issued a Buy, 11.11% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Novartis Ag (NYSE:NVS)

Novartis Ag (NYSE:NVS) is the #3 top general drug manufacturer stock out of 19 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Novartis Ag (NYSE:NVS) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: B, and AI: B.

Novartis Ag (NYSE:NVS) has a Due Diligence Score of 39, which is -3 points lower than the general drug manufacturer industry average of 42. Although this number is below the industry average, our proven quant model rates NVS as a "B".

NVS passed 14 out of 38 due diligence checks and has average fundamentals. Novartis Ag has seen its stock return 5.09% over the past year, overperforming other general drug manufacturer stocks by 19 percentage points.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) has an annual dividend yield of 6.16%, which is 3 percentage points higher than the general drug manufacturer industry average of 3.03%.

Organon & Co's dividend payout ratio of 31.7% indicates that its high dividend yield is sustainable for the long-term.

2. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.47%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.03%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 51% indicates that its high dividend yield is sustainable for the long-term.

3. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) has an annual dividend yield of 4.15%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.03%. Gsk's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Gsk's dividend has not shown consistent growth over the last 10 years.

Gsk's dividend payout ratio of 70.7% indicates that its high dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 0.35% in the last day, and down -0.35% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are up.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 31 points higher than the general drug manufacturer industry average of 40. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -57.78% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -44 percentage points.

2. Merck & Co (NYSE:MRK)

Merck & Co (NYSE:MRK) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Merck & Co has a valuation score of 57, which is 17 points higher than the general drug manufacturer industry average of 40. It passed 4 out of 7 valuation due diligence checks.

Merck & Co's stock has dropped -28.38% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -15 percentage points.

3. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 86, which is 46 points higher than the general drug manufacturer industry average of 40. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has dropped -35.45% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -22 percentage points.

Are general drug manufacturer stocks a good buy now?

42.86% of general drug manufacturer stocks rated by analysts are a hold right now. On average, analysts expect general drug manufacturer stocks to rise by 48.92% over the next year.

10.53% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 52.63% of general drug manufacturer stocks are rated B (Buy), 36.84% are rated C (Hold), 0% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 35.99x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

General Drug Manufacturer Stocks FAQ

1. Grifols Sa (NASDAQ:GRFS)

2. Eli Lilly & Co (NYSE:LLY)

3. Novartis Ag (NYSE:NVS)

1. Organon & Co (NYSE:OGN)

2. Sanofi (NASDAQ:SNY)

3. Gsk (NYSE:GSK)

1. Organon & Co (NYSE:OGN)

2. Merck & Co (NYSE:MRK)

3. Biogen (NASDAQ:BIIB)

Company

Stock Tools

Stock Ideas